Since the credit crunch over a decade ago and one patent cliff after another*, US drug maker behemoth Pfizer has gone through its pipeline troubles seriously challenged, yet has emerged mostly unscathed.

And now, with the Covid-19 vaccine goldmine in sight**, the future may have a completely different taste if a) its magic dose receives the final, green light from the regulators and, equally important b) it gets the logistics angle of its business proposition right.

(*A bit of background is here: 2012, 2014, 2016, ...

Subscription required for Premium stories

In order to view the entire article please login with a valid subscription below or register an account and subscribe to Premium
Premium subscriber
New Premium subscriber REGISTER

Comment on this article

You must be logged in to post a comment.